DK0500953T3 - Potentiator af antineoplastisk virkning og antineoplastisk middel - Google Patents
Potentiator af antineoplastisk virkning og antineoplastisk middelInfo
- Publication number
- DK0500953T3 DK0500953T3 DK91915614.1T DK91915614T DK0500953T3 DK 0500953 T3 DK0500953 T3 DK 0500953T3 DK 91915614 T DK91915614 T DK 91915614T DK 0500953 T3 DK0500953 T3 DK 0500953T3
- Authority
- DK
- Denmark
- Prior art keywords
- antineoplastic
- potentiating
- potentiator
- agent
- antineoplastic effect
- Prior art date
Links
- 230000000118 anti-neoplastic effect Effects 0.000 title abstract 7
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 4
- 239000002246 antineoplastic agent Substances 0.000 title abstract 4
- 230000003389 potentiating effect Effects 0.000 abstract 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 abstract 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 2
- 235000008191 folinic acid Nutrition 0.000 abstract 2
- 239000011672 folinic acid Substances 0.000 abstract 2
- 229960001691 leucovorin Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 abstract 2
- 229960001674 tegafur Drugs 0.000 abstract 2
- 229940035893 uracil Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23871990 | 1990-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0500953T3 true DK0500953T3 (da) | 1997-01-06 |
Family
ID=17034249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK91915614.1T DK0500953T3 (da) | 1990-09-07 | 1991-09-05 | Potentiator af antineoplastisk virkning og antineoplastisk middel |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0500953B1 (da) |
JP (1) | JP2557303B2 (da) |
KR (1) | KR0146952B1 (da) |
AT (1) | ATE141506T1 (da) |
AU (1) | AU644684B2 (da) |
CA (1) | CA2071819A1 (da) |
DE (2) | DE69121551T2 (da) |
DK (1) | DK0500953T3 (da) |
ES (1) | ES2091941T3 (da) |
GR (1) | GR3021003T3 (da) |
HU (1) | HU211739A9 (da) |
LU (1) | LU90791I2 (da) |
NL (1) | NL300041I2 (da) |
WO (1) | WO1992004028A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05310573A (ja) * | 1992-05-01 | 1993-11-22 | Dotsuto:Kk | リウマチ治療薬 |
US5643191A (en) * | 1995-01-26 | 1997-07-01 | Sorin Biomedical Inc. | Cardioplegia delivery system and method for converting from warm cardioplegia to cold cardioplegia |
US5702358A (en) * | 1995-02-23 | 1997-12-30 | Sorin Biomedical Inc. | Cardioplegia delivery apparatus and method of use |
US5660835A (en) * | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
WO2000021956A1 (fr) * | 1998-10-12 | 2000-04-20 | Leonidov Nikolai B | Nouvelle modification cristalline de 5-fluoro-1-(tetrahydro-2-furyl)-uracyle, et composes complexes a base de cette modification ayant une activite antitumorale |
PL1604991T3 (pl) | 2003-03-14 | 2009-02-27 | Taiho Pharmaceutical Co Ltd | Środek wzmacniający działanie przeciwnowotworowe i środek przeciwnowotworowy |
TWI468188B (zh) | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
WO2009139085A1 (ja) | 2008-05-12 | 2009-11-19 | 静岡県 | 抗腫瘍剤、キット及び癌治療方法 |
KR102258514B1 (ko) * | 2019-09-23 | 2021-05-31 | 연세대학교 산학협력단 | 신규한 다층형 좌약 제제 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5953885B2 (ja) * | 1978-02-10 | 1984-12-27 | 大鵬薬品工業株式会社 | 抗腫瘍剤組成物 |
GB2016921B (en) * | 1978-03-27 | 1982-08-18 | Taiho Pharmaceutical Co Ltd | Anti cancer compositions containing uracil derivatives |
JPS5780319A (en) * | 1980-11-06 | 1982-05-19 | Taiho Yakuhin Kogyo Kk | Anti-tumor agent having reduced toxicity |
JPS5838210A (ja) * | 1981-08-31 | 1983-03-05 | Taiho Yakuhin Kogyo Kk | 直腸投与用製剤 |
-
1991
- 1991-09-05 AT AT91915614T patent/ATE141506T1/de active
- 1991-09-05 CA CA002071819A patent/CA2071819A1/en not_active Abandoned
- 1991-09-05 DE DE69121551T patent/DE69121551T2/de not_active Expired - Lifetime
- 1991-09-05 DK DK91915614.1T patent/DK0500953T3/da active
- 1991-09-05 WO PCT/JP1991/001187 patent/WO1992004028A1/ja active IP Right Grant
- 1991-09-05 DE DE10299023C patent/DE10299023I2/de active Active
- 1991-09-05 JP JP3514805A patent/JP2557303B2/ja not_active Expired - Lifetime
- 1991-09-05 ES ES91915614T patent/ES2091941T3/es not_active Expired - Lifetime
- 1991-09-05 EP EP91915614A patent/EP0500953B1/en not_active Expired - Lifetime
- 1991-09-05 AU AU84479/91A patent/AU644684B2/en not_active Expired
- 1991-09-05 KR KR1019920701073A patent/KR0146952B1/ko not_active Expired - Lifetime
-
1995
- 1995-06-30 HU HU95P/P00730P patent/HU211739A9/hu unknown
-
1996
- 1996-09-12 GR GR960402353T patent/GR3021003T3/el unknown
-
2001
- 2001-03-21 NL NL300041C patent/NL300041I2/nl unknown
- 2001-08-06 LU LU90791C patent/LU90791I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP0500953B1 (en) | 1996-08-21 |
AU644684B2 (en) | 1993-12-16 |
HU211739A9 (en) | 1995-12-28 |
DE69121551T2 (de) | 1997-01-02 |
KR0146952B1 (ko) | 1998-08-17 |
CA2071819A1 (en) | 1992-03-08 |
DE10299023I1 (de) | 2003-06-05 |
NL300041I1 (nl) | 2001-06-01 |
GR3021003T3 (en) | 1996-12-31 |
EP0500953A1 (en) | 1992-09-02 |
WO1992004028A1 (fr) | 1992-03-19 |
DE69121551D1 (de) | 1996-09-26 |
ATE141506T1 (de) | 1996-09-15 |
EP0500953A4 (en) | 1993-04-21 |
DE10299023I2 (de) | 2010-05-06 |
JP2557303B2 (ja) | 1996-11-27 |
ES2091941T3 (es) | 1996-11-16 |
NL300041I2 (nl) | 2002-02-01 |
AU8447991A (en) | 1992-03-30 |
KR927002224A (ko) | 1992-09-03 |
LU90791I2 (fr) | 2001-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69318031D1 (de) | Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung | |
LU90334I2 (fr) | Raloxifene et ses sels et dérivés pharmaceutiquement acceptables | |
NL970006I2 (nl) | Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson. | |
ATE108657T1 (de) | Galanthemin enthaltende pharmazeutische formulierung zur behandlung des alkoholismus. | |
DE68926232D1 (de) | Pyrimidine und deren pharmazeutisch brauchbare Salze und deren Verwendung als Arzneimittel | |
PT97785A (pt) | Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina | |
ES2051641A1 (es) | Procedimientos para la preparacion de compuestos derivados de tiourea. | |
DK0768086T3 (da) | Behandling af tinnitus med neurobeskyttende virksomme stoffer | |
SE8801729D0 (sv) | Purine derivatives for use in therapy | |
MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
DK324185D0 (da) | 2-substituerede 1,3-propylidendiphosphonatderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf | |
EP0620004A4 (en) | MEDICAL COMPOSITION. | |
DK0500953T3 (da) | Potentiator af antineoplastisk virkning og antineoplastisk middel | |
ATE82294T1 (de) | Therapeutische nukleoside. | |
DE69029693D1 (de) | Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz | |
DE69222698D1 (de) | 4-desoxy-4-epipodophyllotoxinderivate oder deren pharmazeutisch akzeptierbaren salze | |
BG100599A (en) | Antiviral form and therapeutical method | |
FI934680A0 (fi) | Arylmorfolin, framstaellning och anvaending | |
IL97054A0 (en) | Pharmaceutical compositions comprising buspirones for the treatment of sleep apneas | |
DK0590355T3 (da) | Anvendelse af L-carnitin og acyl-L-carnitiner til behandling af patienter, der lider af AIDS-relaterede syndromer og asymptomatiske HIV-seropositive patienter | |
TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
ES2032476T3 (es) | Un procedimiento para preparar nuevos derivados de 2-anilinotiazolina. | |
PT728002E (pt) | Utilizacao de derivados de 2-amino purina para o tratamento e profilaxia da infeccao pelo virus de herpes 7 humano | |
DK0445894T3 (da) | Anvendelse af tumornekrosefaktor | |
TW207496B (en) | Pharmaceutical composition for preventing or delaying the occurrence of dementia |